ப்ரோக்ரெஸ் போஸ்டர் அமர்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரோக்ரெஸ் போஸ்டர் அமர்வு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரோக்ரெஸ் போஸ்டர் அமர்வு Today - Breaking & Trending Today

Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting

Press release content from Business Wire. The AP news staff was not involved in its creation.
Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
February 4, 2021 GMT
NORTH BILLERICA, Mass. (BUSINESS WIRE) Feb 4, 2021
Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced today three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) Virtual Meeting, which will be held from February 11-13, 2021. Two of the abstracts relate to PyL™, the Company’s PET/CT imaging agent for prostate cancer, and the third ....

New York , United States , Memorial Sloan Kettering Cancer Center , New Jersey , North Billerica , Jeremyc Durack , Frederic Pouliot , Mark Kinarney , Oliver Sartor , Bausch Health Companies Inc , Centre Hospitalier Universitaire , Progenics Pharmaceuticals Inc , Tulane Cancer Center , Lantheus Medical Imaging Inc , Corporate Communications , Lantheus Holdings Inc , Lantheus Medical Imaging , Progenics Pharmaceuticals , Clinical Oncology Genitourinary , Virtual Meeting , Poster Session , Prostate Cancer , Advanced Disease , Progress Poster Session , Advanced Prostate Cancer , Lantheus Holdings ,

Janssen presentará pruebas sólidas de su cartera de tumores sólidos y su cartera de productos en ASCO GU 2021 - Iberonews

ó
stata avanzado; presentaciones orales para destacar los resultados de los estudios de fase 3 ACIS, TITAN y SPARTAN
SOLO PARA MEDIOS DE COMUNICACIÓN MÉDICOS Y COMERCIALES FARMACÉUTICOS DE LA REGIÓN DE EMEA
NO SE PERMITE LA DISTRIBUCIÓN EN EL BENELUX NI EN EL REINO UNIDO
Janssen Pharmaceutical Companies de Johnson & Johnson ha anunciado hoy que destacará la solidez de su cartera de tumores sólidos en el Simposio sobre Cánceres Genitourinarios de la Sociedad Americana de Oncología Clínica (American Society of Clinical Oncology Genitourinary, ASCO GU) con 12 presentaciones de datos, entre las que se incluyen tres presentaciones orales del programa de desarrollo clínico de apalutamida patrocinadas por la compañía. ....

Prognostic Association Between Common Laboratory , Single Payer Health , Determinants Associated , Long Term Response , Non Metastatic Castration Resistant Prostate , Placebo Controlled Double Blind Phase , Abiraterone Acetate Plus Prednisone , Prostate Cancer , Advanced Disease , Related Quality , Life Analysis , Randomized Phase , Androgen Signaling Inhibitors , Androgen Deprivation Therapy , Castration Sensitive Prostate Cancer , Unsatisfactory Response , Androgen Receptor Inhibition , Allocation Modular Sequential , Radiation Therapy Followed , Prostate Cancer After Radical , Locally Advanced , Metastatic Urothelial , Urothelial Carcinoma , Deleterious Germline , Progress Poster Session , Advanced Prostate Cancer ,

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
Multiple data presentations to show long-term benefit and consistency of ERLEADA® (apalutamide) in advanced prostate cancer; oral presentations to highlight Phase 3 ACIS, TITAN and SPARTAN study results
News provided by
Share this article
Share this article
RARITAN, N.J., Feb. 2, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA
® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. ....

United States , Craig Tendler , Jennifer Mcintyre , Christopher Delorefice , Obrian Kenney , Global Medical Affairs , Breadth Of Ongoing Clinical Development Program , Janssen Biotech Inc , Tesaro Inc , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Laboratory Abnormalities , Prognostic Association Between Common Laboratory , Clinical Development , None Of The Janssen Pharmaceutical Companies , Astex Pharmaceuticals , Janssen Research Development Llcor , Exchange Commission , Companies Of Johnson , Single Payer Health , American Society , Clinical Oncology Genitourinary , Cancers Symposium , Vice President , Janssen Research ,

Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium

News Category Global Banking & Finance Reviews
Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium
Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary data from the ongoing dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in combination with zimberelimab (anti-PD-1) and nab-paclitaxel plus gemcitabine (chemotherapy) in front-line metastatic pancreatic cancer will be presented in a poster session at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI) being held January 15 ....

United States , Katherine Bock , Arcus Biosciences Inc , Arcus Biosciences , Gastrointestinal Cancers Symposium , Bill Grossman , Chief Medical Officer , Poster Title , Pancreatic Cancer Available Date , Progress Poster Session , Colorectal Cancer Available Date , Private Securities Litigation Reform Act , Nat Rev Dis , Invest New , Clin Cancer , ஒன்றுபட்டது மாநிலங்களில் , க்யாதரிந் போக் , ஆர்கஸ் உயிர் அறிவியல் இன்க் , ஆர்கஸ் உயிர் அறிவியல் , இரைப்பை குடல் புற்றுநோய்கள் சிம்போசியம் , ர சி து மொத்த மனிதர் , தலைமை மருத்துவ அதிகாரி , போஸ்டர் தலைப்பு , கணையம் புற்றுநோய் கிடைக்கிறது தேதி , ப்ரோக்ரெஸ் போஸ்டர் அமர்வு , பெருங்குடல் புற்றுநோய் கிடைக்கிறது தேதி ,

Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

/PRNewswire/ Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing new treatment options for cancer patients in. ....

United States , Karen Oshea , Danielh Ahn , Mark Erlander , Vicki Kelemen , Daniel Ahn , Joyce Allaire , Cardiff Oncology Inc , Cancer Center , Exchange Commission , Kansas University Medical Center , Lifesci Communications , Norris Comprehensive Cancer Center , Mayo Clinic Cancer Centers Arizona , Mayo Clinic Cancer Center , Access Program , Cardiff Oncology , American Society , Expanded Access , Comprehensive Cancer Center , Mayo Clinic Cancer Centers , Progress Poster Session , Colorectal Cancer , Poster Presentation , Line Treatment , Metastatic Colorectal Cancer ,